Search research articles
Contact Us
Filters
Showing results (531-540 of 542) with videos related to
Page
of 55
Sort By:
Journal of Cancer
|
November 19, 2019
The impact of Adult Comorbidity Evaluation-27 on the clinical outcome of elderly nasopharyngeal carcinoma patients treated with chemoradiotherapy or radiotherapy: a matched cohort analysis
Yue-Feng Wen, Xue-Song Sun, Li Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2022
Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial
Xiao-Yun Li, Dong-Hua Luo, Ling Guo, et al.
Nature Communications
|
March 31, 2026
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial
Li-Ting Liu, Xue-Song Sun, Ting-Ting Quan, et al.
JAMA Oncology
|
June 18, 2025
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial
Shan-Shan Guo, Xiao-Yun Li, Li-Ting Liu, et al.
The Lancet. Oncology
|
November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial
Sai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
The Lancet. Oncology
|
June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
Li-Ting Liu, Huai Liu, Ying Huang, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 1, 2025
[<sup>18</sup>F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma
Li-Ting Liu, Zhen-Chong Yang, Jia-Rui He, et al.
Eclinicalmedicine
|
November 17, 2025
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial
Yu-Chen Li, Xiao-Yun Li, Kai-Qi Lan, et al.
Cell
|
February 13, 2016
Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing
Xinping Yang, Jasmin Coulombe-Huntington, Shuli Kang, et al.
The Lancet. Oncology
|
March 5, 2018
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial
Lin-Quan Tang, Dong-Ping Chen, Ling Guo, et al.
Page
of 55
Search research articles
Search
Showing results (531-540 of 542) with videos related to
Sort By:
Page
of 55
Journal of Cancer
|
November 19, 2019
The impact of Adult Comorbidity Evaluation-27 on the clinical outcome of elderly nasopharyngeal carcinoma patients treated with chemoradiotherapy or radiotherapy: a matched cohort analysis
Yue-Feng Wen, Xue-Song Sun, Li Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2022
Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial
Xiao-Yun Li, Dong-Hua Luo, Ling Guo, et al.
Nature Communications
|
March 31, 2026
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial
Li-Ting Liu, Xue-Song Sun, Ting-Ting Quan, et al.
JAMA Oncology
|
June 18, 2025
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial
Shan-Shan Guo, Xiao-Yun Li, Li-Ting Liu, et al.
The Lancet. Oncology
|
November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial
Sai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
The Lancet. Oncology
|
June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
Li-Ting Liu, Huai Liu, Ying Huang, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 1, 2025
[<sup>18</sup>F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma
Li-Ting Liu, Zhen-Chong Yang, Jia-Rui He, et al.
Eclinicalmedicine
|
November 17, 2025
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial
Yu-Chen Li, Xiao-Yun Li, Kai-Qi Lan, et al.
Cell
|
February 13, 2016
Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing
Xinping Yang, Jasmin Coulombe-Huntington, Shuli Kang, et al.
The Lancet. Oncology
|
March 5, 2018
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial
Lin-Quan Tang, Dong-Ping Chen, Ling Guo, et al.
Page
of 55